Oral antifungal medications are widely used in children to treat infections ranging from common scalp ringworm to life-threatening invasive fungal disease in immunocompromised patients. The choice of drug, dose, and treatment duration depends heavily on the type of fungus involved, the child’s age, and what other medications they are taking. What makes pediatric antifungal therapy distinct from adult treatment is that children metabolize many of these drugs faster, sometimes requiring higher weight-based doses to reach effective blood levels. And for the sickest children, the margin between an effective dose and a toxic one can be uncomfortably thin.
Scalp Ringworm and the Griseofulvin-Versus-Terbinafine Question
Tinea capitis, or fungal infection of the scalp, is the most common reason otherwise healthy children are prescribed an oral antifungal. Topical creams do not penetrate the hair follicle well enough to clear these infections, so systemic therapy is the standard approach. For decades griseofulvin was the only option, taken daily for six to eight weeks. Terbinafine arrived as a faster alternative, typically requiring only two to four weeks of treatment. The question of which drug works better has been studied in multiple randomized trials.
The answer depends on which fungus is causing the infection. Two meta-analyses of randomized trials reached the same core conclusion: terbinafine performs better against Trichophyton species, while griseofulvin is the stronger choice against Microsporum species. One meta-analysis found that a two-to-four-week course of terbinafine was at least as effective as a six-to-eight-week course of griseofulvin for Trichophyton scalp infections.1PubMed. Griseofulvin versus terbinafine in the treatment of tinea capitis: a meta-analysis of randomized, clinical trials A later meta-analysis confirmed that terbinafine was significantly more effective for Trichophyton, while griseofulvin was significantly more effective for Microsporum.2PubMed. Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis In practice, the species causing the infection often varies by geography. In much of North America and the UK, Trichophyton tonsurans predominates, making terbinafine the more practical choice. In parts of continental Europe and Africa, Microsporum canis is more common, which tips the balance toward griseofulvin.
The practical difference matters to families: a two-to-four-week course of terbinafine is much easier to complete than six to eight weeks of griseofulvin. Griseofulvin also needs to be taken with a fatty meal to improve absorption, which can be a nuisance. Terbinafine comes as granules that can be sprinkled on food, making dosing easier for younger children who struggle with pills. These day-to-day factors often influence the prescribing decision as much as the microbiological data.
Oral Thrush in Infants
Oral candidiasis, commonly called thrush, is extremely common in babies. The white patches on the tongue and inner cheeks are caused by Candida yeast overgrowth. Nystatin suspension has been the traditional treatment for decades because it stays in the mouth and is barely absorbed into the bloodstream, which seems like an advantage for a baby. But the evidence suggests it does not work very well.
A randomized trial comparing nystatin to fluconazole in otherwise healthy infants found that fluconazole cleared thrush in all fifteen infants who received it, while nystatin cured only about a third of those treated.3PubMed. Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants A systematic review and meta-analysis pooling multiple studies in infants, children, and immunocompromised patients confirmed that nystatin suspension was significantly less effective than fluconazole.4PubMed Central. Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis Fluconazole also has the convenience of once-daily dosing for seven days, whereas nystatin requires four doses per day for ten days. Despite the stronger evidence for fluconazole, many clinicians still prescribe nystatin as a first-line agent for mild thrush in healthy babies, partly out of habit and partly because nystatin’s lack of systemic absorption feels intuitively safer. For persistent or recurrent cases, though, the data clearly favors fluconazole.
Why Children Need Different Doses Than Adults
A child is not simply a small adult, and antifungal dosing reflects this. In newborns, the kidneys and liver are still maturing, and the rate at which drugs are cleared changes rapidly in the first weeks of life. Fluconazole clearance roughly doubles between birth and twenty-eight days of age.5PubMed Central. Pharmacokinetics and Pharmacodynamics of Antifungals in Children and Their Clinical Implications Beyond the newborn period, children generally clear many antifungals faster than adults do. This means that using adult-style dosing often leads to blood levels that are too low to fight the infection effectively.
Voriconazole is a striking example. Studies have shown that children require roughly twice the recommended adult dose to reach comparable blood concentrations.6PubMed Central. Pharmacokinetics and Pharmacodynamics of Antifungals in Children and their Clinical Implications This difference is large enough that underdosing is a real clinical problem. In one study of pediatric patients receiving voriconazole, only about half achieved blood levels within the target therapeutic range, while roughly forty percent had levels that were too low.7PubMed Central. Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients Those subtherapeutic levels represent a real risk: the child is dealing with side effects from a drug that is not reaching concentrations high enough to fight the fungus.
The Genetic Wild Card in Voriconazole Dosing
Voriconazole is metabolized primarily by an enzyme called CYP2C19, and the gene encoding that enzyme varies substantially from person to person. Some people are rapid metabolizers who break the drug down quickly, ending up with low blood levels. Others are poor metabolizers who clear the drug slowly, accumulating higher and potentially toxic concentrations. These genetic differences have outsized effects in children.
A study in pediatric patients found that age, CYP2C19 genetic status, and concurrent use of certain stomach-acid medications together accounted for nearly a quarter of the variability in voriconazole blood levels. Children who were poor metabolizers had significantly higher drug concentrations than those who were normal metabolizers.8PubMed Central. Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients Population pharmacokinetic modeling has suggested that optimal dosing should vary by genotype: normal metabolizers may need oral doses around 9 mg/kg twice daily, while poor metabolizers could use as little as 6 mg/kg twice daily.7PubMed Central. Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients
This variability is why therapeutic drug monitoring, where blood levels of the drug are measured directly, has become standard practice for voriconazole in children. Consensus guidelines from pediatric infectious disease societies recommend specific trough concentration targets for both prophylaxis and active treatment, with adjustments if infections involve fungi with higher resistance thresholds or if the infection is in a hard-to-reach location such as bone or the central nervous system.9Anales de PediatrÃa (English Edition). Therapeutic Drug Monitoring of antibiotic and antifungical drugs in paediatric and newborn patients Without monitoring, doctors are essentially guessing whether the dose is right.
Preventing Invasive Fungal Infections After Transplant
Children who receive bone marrow or stem cell transplants are profoundly immunosuppressed and at high risk for invasive fungal infections caused by molds like Aspergillus and yeasts like Candida. Oral antifungal prophylaxis, where the drug is given preventively rather than to treat an active infection, is standard care in these patients. Three triazole drugs are commonly used for this purpose: itraconazole, voriconazole, and posaconazole.
A comparative study of fifty consecutive pediatric patients in each drug group found that all three agents were similarly effective at preventing proven or probable invasive fungal infection after transplant. No confirmed invasive mycosis occurred in any of the three groups. Adverse events that could be related to the antifungal were seen in about 14 percent of the voriconazole group, 12 percent of the itraconazole group, and 8 percent of the posaconazole group.10SpringerLink (Eur J Clin Microbiol Infect Dis). Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation The choice among them often comes down to drug interactions, the availability of child-friendly formulations, and how well a particular child tolerates the medication.
Safety Concerns With Oral Antifungals in Children
The safety profile of an antifungal matters differently depending on whether you are treating a healthy child’s ringworm or keeping a transplant patient alive. For common superficial infections treated with griseofulvin or terbinafine, the drugs are generally well tolerated. A large retrospective study looking at laboratory monitoring in both adults and children taking terbinafine or griseofulvin for skin and nail fungal infections found that abnormalities were rare. Among children, only one had a clinically significant liver enzyme elevation that led to stopping the medication.11JAMA Dermatology. Utility of Laboratory Test Result Monitoring in Patients Taking Oral Terbinafine or Griseofulvin for Dermatophyte Infections For short treatment courses of a few weeks, routine blood monitoring is considered low yield by many dermatologists, though it is still often done.
Voriconazole carries more serious risks. One of the concerns is its effect on heart rhythm. A study of pediatric patients on voriconazole found that the average QTc interval, a marker of heart rhythm timing, increased from about 403 milliseconds before treatment to 440 milliseconds during treatment. Roughly 18 percent of children developed a QTc interval of 500 milliseconds or more, a threshold associated with dangerous rhythm abnormalities. One patient developed torsades de pointes, a potentially fatal arrhythmia.12PubMed. Voriconazole-induced QTc prolongation in a paediatric population A pharmacovigilance analysis using a large adverse-event database found that triazole antifungals as a class were associated with a higher reporting odds for QT prolongation and torsades de pointes, including in younger patients.13PubMed Central. Association of Torsade de Pointes and QT Prolongation With Antifungal Triazoles: Analysis Using a Pharmacovigilance Database Older age within the pediatric range, low potassium levels, and a longer baseline QTc at the start of treatment were associated with greater QTc prolongation.12PubMed. Voriconazole-induced QTc prolongation in a paediatric population This is why electrocardiograms and electrolyte monitoring are part of routine care for children on voriconazole.
Drug Interactions in Immunocompromised Children
Many children who need oral antifungals are also taking other powerful medications: immunosuppressants after organ or stem cell transplants, chemotherapy for cancer, or corticosteroids for inflammatory conditions. The azole antifungals are notorious for interacting with other drugs because they inhibit the same liver enzymes that metabolize many medications.
In transplant patients, the interaction between azoles and immunosuppressants like tacrolimus and cyclosporine is a constant clinical challenge. Azoles block the liver enzymes that clear these drugs, causing immunosuppressant levels to spike. If the immunosuppressant level climbs too high, the child faces kidney damage or other organ toxicity. If a clinician preemptively cuts the immunosuppressant dose but miscalculates, the child risks transplant rejection.14PubMed. Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice Managing this balancing act requires frequent blood level monitoring of both the antifungal and the immunosuppressant, sometimes multiple times per week during the initial overlap period.
Children with cancer face a related problem. Vincristine, a widely used chemotherapy drug, is metabolized by the same enzyme pathway that azoles inhibit. When the two drugs overlap, vincristine clearance slows and toxicity risk rises, potentially causing nerve damage. The interaction is recognized but difficult to study rigorously in children because of ethical constraints around randomization in sick patients.15PubMed. Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation In practice, many oncologists try to avoid concurrent azole use during vincristine cycles or switch to an antifungal that does not affect the same enzymes.
Formulation Challenges and Getting Kids to Take the Medicine
An antifungal that works perfectly in the lab is useless if the child spits it out. Pediatric drug formulation is a real and underappreciated obstacle. Many oral antifungals were originally designed for adults and later adapted for children, sometimes poorly. Issues include suspensions that require large volumes because the drug concentration is too low, granules with a gritty texture that children find unpleasant, and bitter-tasting medications that resist masking even with flavoring agents.16PubMed. Drug Formulation for Pediatric Oral Antimicrobial Agents in Japan: Current Status, Prospects, and Challenges
Nystatin suspension is a good example: it tastes distinctly unpleasant to many infants, and it needs to be applied four times a day. Fluconazole suspension, by contrast, comes in a flavored formulation dosed once daily, which is far easier for parents to administer. Itraconazole oral solution has a notably bitter taste and is sometimes poorly tolerated. These practical realities influence treatment adherence and, ultimately, outcomes. A course of medication that a child refuses to finish is as ineffective as no treatment at all.
Growing Resistance to Antifungals
Antifungal resistance is a less publicized but increasingly serious problem. Unlike antibacterial resistance, which dominates public health campaigns, fungal resistance receives comparatively little attention. Fluconazole resistance is the most widespread concern. Among Candida auris, a species that has emerged as a global threat in healthcare settings, about 93 percent of isolates are resistant to fluconazole.17PubMed Central. Understanding the mechanisms of resistance to azole antifungals in Candida species Resistance develops through several routes, including changes in the enzyme that azoles target, pumps that push the drug out of the fungal cell before it can act, and alterations in the cell’s sterol-making machinery.
Overuse and inappropriate prescribing of antifungals in children contributes to this problem. Antifungal stewardship, the practice of ensuring that these drugs are used only when needed and at the right dose and duration, is gaining traction in pediatric hospitals. Inappropriate prescribing has been documented in pediatric settings and leads not only to resistance but also to unnecessary adverse events.18SpringerLink / Mycopathologia. Antifungal Prescription and Stewardship in Pediatrics Getting the diagnosis right before reaching for an antifungal is a key part of stewardship. In critically ill children with suspected pulmonary fungal infections, procedures like bronchoalveolar lavage can identify the specific organism and guide therapy, sometimes leading to changes in the antifungal regimen that would not have happened based on empiric treatment alone.19Turkish Journal of Pediatric Disease. Bronchoalveolar lavage: A key tool in pulmonary fungal infection management
New Oral Antifungals on the Horizon
The antifungal pipeline has been relatively quiet compared to antibacterial drug development, but a few newer agents are generating interest for pediatric use. Ibrexafungerp is one of the most watched. It works by a different mechanism than azoles, targeting the same cell-wall enzyme that echinocandins hit but binding at a distinct site. What makes ibrexafungerp especially relevant for children is that it is available as an oral formulation. Echinocandins, which are among the most effective drugs for invasive Candida infections, can only be given intravenously. Ibrexafungerp could serve as an oral step-down option, allowing children to leave the hospital sooner or avoid an IV line altogether. It has activity against Candida auris and other resistant Candida species, as well as Aspergillus, including some strains that resist triazoles.20Journal of the Pediatric Infectious Diseases Society. Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective An intravenous formulation is in early-phase development. Pediatric dosing studies are still underway, but the drug’s oral bioavailability and broad spectrum make it one of the more promising candidates for expanding the limited antifungal toolkit available to children.
What Antifungals Do to the Gut
An underappreciated consequence of oral antifungal therapy in children, especially those who are immunocompromised and often receiving antibiotics at the same time, is the effect on the gut microbiome. A study of pediatric leukemia and lymphoma patients found that both antibiotics and antifungals were associated with a decline in gut microbial diversity. Specifically, antifungal use was linked to a decrease in bacteria that produce butyrate, a short-chain fatty acid critical for maintaining the integrity of the intestinal lining and supporting the immune system. At the same time, antifungal exposure was associated with a significant increase in the abundance of opportunistic pathogens in the gut.21PubMed Central. Antibiotic and antifungal use in pediatric leukemia and lymphoma patients are associated with increasing opportunistic pathogens and decreasing bacteria responsible for activities that enhance colonic defense
This creates a troubling paradox: the drugs used to protect vulnerable children from fungal infection may simultaneously weaken the gut’s natural defenses and create an environment that fosters other harmful organisms. The clinical significance of these microbiome shifts is still being studied, but it adds another layer to the calculus of antifungal stewardship. Using these drugs judiciously and for the shortest effective duration is not just about preventing resistance; it is about preserving the child’s broader ecosystem of protective microbes during a time when their immune system can least afford additional insults.